InMed Pharmaceuticals Inc. (INM) Form 8-K — Nov 16, 2026
InMed Pharmaceuticals completed its reverse merger with Mentari Therapeutics on November 6, 2026, with the combined company renamed Mentari Therapeutics, Inc. and led by Mentari's management, focused on migraine-prevention antibodies MT-001 through MT-005. Former Mentari securityholders own approximately 99.0% of the combined company on a fully diluted basis, while former InMed holders retain roughly 1.0%, with InMed valued at just $5.6 million in the deal.
Key figures
- Cash Position
- 45791000
- Gross Proceeds
- 490000000
- Total assets
- 52440000
- Rd expense q3
- 28442000
- Exchange ratio
- 0.20065
- Reverse split ratio
- 1:10
- Convertible note rate
- 12.0%
- First price per share
- 1.8928
- Former inmed ownership
- 1.0%
- Rd expense nine months
- 57709000
- Second price per share
- 2.8923
- Former mentari ownership
- 99.0%
- Convertible note principal
- 50000000
- First preclosing financing
- 290000000
- Inmed valuation at closing
- 5600000
- Second preclosing financing
- 200000000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.